Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul class="summary-list"><li><keyword id="12954246" type="UNKNOWN" weightage="60" keywordseo="novavax" source="Orion">Novavax</keyword> and <keyword id="11901412" type="UNKNOWN" weightage="60" keywordseo="moderna" source="Orion">Moderna</keyword> shares were under pressure Friday after the Supreme Court struck down a vaccine mandate for private companies. </li><li>The ruling blocked the Biden administration's vaccine-or-testing mandate at private companies with more than 100 employees. </li></ul>Shares of Novavax and Moderna trimmed losses Friday after the Biden administration's vaccine-or-testing mandate for certain private companies was blocked by the Supreme Court. In a <a href="https://www.businessinsider.com/supreme-court-biden-vaccine-testing-mandate-covid-19-2022-1">6-3 ruling issued Thursday afternoon</a>, the court's conservative majority wrote in an unsigned <a href="https://www.supremecourt.gov/opinions/21pdf/21a244_hgci.pdf">opinion</a> that the administration likely didn't hold the authority to impose its policy. <a href="https://markets.businessinsider.com/stocks/nvax-stock">Novavax</a> shares slumped 10% to $101.10 then pared the loss to 5%. <a href="https://markets.businessinsider.com/stocks/mrna-stock">Moderna</a> declined 3.5% to $202.88 before narrowing the pullback to 2.8%. Novavax stock closed Thursday's session down by 13.7% at $112.38, the lowest closing price since December 2020. For Moderna, its 5.7% fall in the previous session to $210.17 marked the lowest close since June 2021. Shares of vaccine maker <a href="https://markets.businessinsider.com/stocks/pfe-stock">Pfizer</a> were down by a more modest 0.6%. The stock finished Thursday with a 2% loss. "Although COVID-19 is a risk that occurs in many workplaces, it is not an occupational hazard in most," the court wrote.The mandate had been put in place for private companies with a workforce of more than 100 employees. The court's liberal justices Stephen Breyer, Elena Kagan, and Sonia Sotomayor held the dissenting opinion of the majority's ruling. The court did allow the Biden administration's requirement for vaccines for healthcare workers at federally funded facilities to take effect.

Moderna and Novavax pare losses after Supreme Court strikes down Biden's vaccine mandate for private employers

<ul class="summary-list"><li><keyword id="323030" type="COMPANY" weightage="60" keywordseo="Novavax">Novavax</keyword> shares jumped more than 20% on Wednesday following a COVID-19 vaccine supply agreement in Europe. </li><li>EU member states can purchase up to 200 million doses of the biotech company's vaccine starting in Q4 2021. </li><li>The deal is subject to the vaccine's approval by the <keyword id="6355110" type="DEFINITION" weightage="60" keywordseo="european-union">European Union</keyword>'s drugs regulator. </li></ul>Shares of <a href="https://markets.businessinsider.com/stocks/nvax-stock">Novavax</a> shot up by more than 20% on Wednesday following the biotech company's agreement in Europe to sell millions of doses of its potential COVID-19 vaccine, a deal reached as the Delta strain of the disease spearheads an increase in cases worldwide. The <keyword id="59149" type="ORGANIZATION" weightage="60" keywordseo="European-Commission">European Commission</keyword> said its member states will be able to purchase up to 100 million doses of Novavax's vaccine beginning in the fourth quarter of 2021 and in 2022. The deal is subject to approval of the vaccine candidate following a review by the European Union's drugs regulator. Financial terms were not disclosed <a href="https://ec.europa.eu/commission/presscorner/detail/en/ip_21_4061">in a statement from the commission</a>. The EU has the option to buy another 100 million doses over the course of 2021 to 2023. Novavax shares jumped 23% to an intraday high of $231.09, the highest price since early May. The stock has more than doubled this year. "As new coronavirus variants are spreading in Europe and around the world, this new contract with a company that is already testing its vaccine successfully against these variants is an additional safeguard for the protection of our population," said Ursula von der Leyen, president of the EC, in the statement. The bloc already has vaccine supply deals with <a href="https://markets.businessinsider.com/stocks/pfe-stock">Pfizer</a> and its partner <a href="https://markets.businessinsider.com/stocks/bntx-stock">BioNTech,</a> <a href="https://markets.businessinsider.com/stocks/mrna-stock">Moderna,</a> <a href="https://markets.businessinsider.com/stocks/azn-stock">AstraZeneca</a>, and other companies and said the Novavax deal broadens its portfolio. Countries across Europe have been reporting a rise in cases as the highly transmissible Delta strain spreads. Infections have been moving higher since mid-June, with the seven-day average in France hitting more than 21,000 cases over the last two weeks and reaching nearly 5,500 in Italy, according to data collected by Reuters. Novavax in June said its COVID-19 vaccine had an overall 90.4% efficacy rate. The company was aiming to submit emergency use approval documents to the US Food and Drug Administration by September.Separately, <a href="https://markets.businessinsider.com/news/stocks/moderna-pfizer-stock-retail-investors-covid-delta-vaccines-180-million-2021-8">retail investors have bought more stock in Moderna and Pfizer</a> in recent sessions than they have since November when the companies each announced positive COVID-19 vaccine results, according to data released Wednesday by Vanda Research, which tracks retail investor activity in the US.

Novavax surges 23% after scoring COVID-vaccine supply deal with the EU

<ul><li><a href="https://markets.businessinsider.com/stocks/nvax-stock">Novavax</a> erased early losses and gained as much as 11.4% on Monday after updating investors on its various COVID-19 <keyword id="9237535" type="UNKNOWN" weightage="60" keywordseo="vaccine-trials">vaccine trials</keyword>.</li><li>The biotech company announced it completed enrollment of its 15,000-participant study in the UK, according to a <a href="https://ir.novavax.com/news-releases/news-release-details/novavax-announces-covid-19-vaccine-clinical-development-progress">press release</a>. Interim data from the phase 3 trial is expected as early as the first quarter of 2021.</li><li>The news wasn't all good. The firm delayed its US and Mexico study for the second time, and now expects the phase 3 trial to begin "in the coming weeks."</li><li>Though <keyword id="323030" type="COMPANY" weightage="60" keywordseo="Novavax">Novavax</keyword> lags <a href="https://markets.businessinsider.com/stocks/pfe-stock">Pfizer</a>, <a href="https://markets.businessinsider.com/stocks/mrna-stock">Moderna</a>, and <a href="https://markets.businessinsider.com/stocks/azn-stock">AstraZeneca</a> in winning regulatory approval, it's still on track to begin rolling out its vaccines next year should the shot prove effective.</li><li><a href="https://markets.businessinsider.com/stocks/nvax-stock">Watch Novavax trade live here</a>.</li></ul><a href="https://markets.businessinsider.com/stocks/nvax-stock">Novavax</a> retraced a premarket slump and jumped as much as 9.7% on Monday after offering updates to various COVID-19 vaccine studies.The biotech company announced Monday that it completed enrollment of its 15,000-participant trial in the UK. Interim data from the phase 3 study is expected as soon as the first quarter of 2021. Timing is still contingent on the coronavirus infection rate in the UK, according to a <a href="https://ir.novavax.com/news-releases/news-release-details/novavax-announces-covid-19-vaccine-clinical-development-progress">press release</a>. If successful, the data can support applications for regulatory approval in the UK and European Union.News from other late-stage trials was less than stellar. Novavax's US and Mexico trial was expected to start in October but will now begin "in the coming weeks," according to the release. That phase 3 study had already been delayed to late November. Read more: <a href="https://www.businessinsider.com/stock-picks-to-buy-covid-recovery-value-rotation-undervalued-rbc-2020-11">Buy these 10 stocks set to soar and smash Wall Street's expectations in the recovery from COVID-19, RBC says</a>Novavax initially fell as much as 7% in premarket trading as the second trial delay cut into bullishness. Shares quickly rebounded after the market opened and hit an intraday high of $137.85 before paring some gains.The rally adds to a colossal year-to-date gain for the Gaithersburg, Maryland-based firm. Novavax shares have climbed roughly 3,337% in 2020 as investors bet on the firm's vaccine candidate to be distributed worldwide. Monday's jump places shares at their highest levels since July.Other pharmaceutical and biotech companies have already revealed successful trial results and are on the verge of distributing their vaccines in late 2020 or early 2021. <a href="https://markets.businessinsider.com/stocks/pfe-stock">Pfizer</a> and <a href="https://markets.businessinsider.com/stocks/bntx-stock">BioNTech</a> lead the vaccine race, having applied for emergency-use authorization earlier this month. <a href="https://markets.businessinsider.com/stocks/mrna-stock">Moderna</a> plans to <a href="https://www.businessinsider.com/moderna-coronavirus-covid-vaccine-emergency-use-authorization-fda-2020-11">apply for authorization</a> today.<a href="https://markets.businessinsider.com/stocks/azn-stock">AstraZeneca</a> and Oxford University will likely retest their vaccine after an error potentially skewed results in a recent study.Though it lags some peers, Novavax is still on track to win regulatory approval and begin rolling out its shot next year should the vaccine prove effective. The company's candidate uses spike proteins to protect patients from COVID-19, while Moderna and Pfizer's vaccines both use m-RNA.Novavax traded at $136.96 per share at 11:10 a.m. ET Monday. The company has 22 "buy" ratings, two "hold" ratings, and one "sell" rating from analysts.Now read more <keyword id="31671" type="CITY" weightage="100" keywordseo="markets">markets</keyword> coverage from Markets Insider and Business Insider:<a href="https://markets.businessinsider.com/news/stocks/slack-stock-price-salesforce-deal-announced-tuesday-premium-work-crm-2020-11-1029849354">Slack surges 7% on report that Salesforce takeover will be announced Tuesday afternoon at a premium</a><a href="https://markets.businessinsider.com/currencies/news/guggenheim-fund-bitcoin-investment-cryptocurrency-market-rally-grayscale-trust-btc-2020-11-1029849060">Guggenheim says it could invest up to $530 million in a bitcoin trust as the cryptocurrency flirts with new record highs</a><a href="https://www.businessinsider.com/goldman-sachs-esg-trends-markets-climate-investing-stock-sustainability-social-2020-11">A top equity portfolio strategist at Goldman Sachs shares his four essential ESG trends that you need to be thinking about</a><a href="https://markets.businessinsider.com/stocks/nvax-stock"><div type="image" title="NVAX" height="1086" width="1434" msid="79497350" hostid="261"></div></a>

Novavax climbs 11% after announcing data from UK vaccine trial are expected in early 2021

<ul class="summary-list"><li><keyword id="323030" type="COMPANY" weightage="60" keywordseo="Novavax">Novavax</keyword> shares climbed as much as 9% on Monday following the biotech firm's upbeat data about its potential <keyword id="8904563" type="UNKNOWN" weightage="60" keywordseo="covid-19-vaccine">COVID-19 vaccine</keyword>. </li><li>The study of nearly 30,000 people in the US and Mexico produced an overall efficacy rate of 90.4%. </li><li>The company is aiming to file for <keyword id="6354656" type="ORGANIZATION" weightage="60" keywordseo="fda">FDA</keyword> approval in the third quarter of this year. </li></ul><a href="https://markets.businessinsider.com/stocks/nvax-stock">Novavax</a> shares climbed as much as 9% on Monday after the company said a late-stage study of its experimental <keyword id="8763838" type="UNKNOWN" weightage="60" keywordseo="covid-19">COVID-19</keyword> vaccine showed efficacy of more than 90% in nearly 30,000 people. The results move the company closer to seeking authorization for its use in the US. The company said it plans on filing for regulatory approval of NVX-CoV2373 with the Food and Drug Administration in the third quarter and upon receiving clearance it would remain on track to reach manufacturing capacity of 100 million doses per month by the end of the third quarter. It also foresees hitting manufacturing capacity of 150 million doses per month by the end of the fourth quarter. Novavax traded 2% higher as of 9:55 a.m. in New York, and has now gained more than 90% year-to-date.Novavax's phase 3 study of 29,960 participants in 119 sites in the US and Mexico overall efficacy of 90.4% after observing 77 COVID-19 cases among the participants, with 63 in the placebo group and 14 in the vaccine group. It said the potential vaccine demonstrated 100% protection against moderate and severe disease. The vaccine is administered in two doses and preliminary safety data from the Prevent-19 study showed the potential product to be generally well-tolerated."These data show consistent, high levels of efficacy and reaffirm the ability of the vaccine to prevent COVID-19 amid ongoing genetic evolution of the virus," said Gregory Glenn, M.D., president of Research and Development at Novavax, in a statement. The company said further analyses of the trial are ongoing and that data will be submitted to peer-review journals for publication. It also said the placebo-controlled portion of its study of 2,248 adolescents ranging from 12 years to less than 18 years of age continues. <a href="https://www.businessinsider.com/novavax-stock-price-plunges-delay-covid-vaccine-approval-fda-biotech-2021-5">In May, the company's shares slid</a> to the $121 range after Novavax said it was delaying seeking approval for its COVID-19 vaccine from three regulators, including the Food and Drug Administration, because of manufacturing issues.Read more: <a href="https://www.businessinsider.com/stocks-to-buy-meme-stocks-amc-gamestop-reddit-best-short-squeeze-fintelio" target="_blank" rel="noopener">These 5 stocks are prime candidates for an explosive AMC-style short squeeze right now, according to data from Fintel.io</a>

Novavax climbs 9% after clinical trial shows the firm's COVID-19 vaccine is 90% effective

<ul><li><a href="https://markets.businessinsider.com/stocks/nvax-stock">Novavax</a> shares leaped as much as 13.3% on Friday after finalizing a deal with the UK to supply 60 million doses of its potential <keyword id="8624004" type="UNKNOWN" weightage="60" keywordseo="coronavirus-vaccine">coronavirus vaccine</keyword>.</li><li>The biotech company didn't reveal how much the UK paid for the doses.</li><li>The UK government will collaborate with <keyword id="323030" type="COMPANY" weightage="60" keywordseo="Novavax">Novavax</keyword> on phase 3 trials of its NVX-CoV2373 vaccine, according to a <a href="https://ir.novavax.com/news-releases/news-release-details/novavax-and-uk-government-announce-collaboration-and-purchase">press release</a>.</li><li><a href="https://markets.businessinsider.com/stocks/nvax-stock">Watch Novavax trade live here</a>.</li></ul><a href="https://markets.businessinsider.com/stocks/nvax-stock">Novavax</a> rallied as much as 13.3% on Friday after reaching a deal with the UK for 60 million doses of its coronavirus vaccine.The biotech company did not reveal how much the government paid for the potential vaccine. Novavax will partner with the UK government for phase 3 trials of its NVX-CoV2373 vaccine, according to a <a href="https://ir.novavax.com/news-releases/news-release-details/novavax-and-uk-government-announce-collaboration-and-purchase">press release</a>. The study will involve roughly 9,000 adults in the UK aged between 18 and 85 and is set to begin in the third quarter of 2020."We believe that Novavax has a highly innovative vaccine that could be the first in its class of protein-based vaccine options," Kate Bingham, chair of the UK government's Vaccines Taskforce, said in a statement, adding that Novavax's recent clinical data is "encouraging."Read more: <a href="https://www.businessinsider.com/gold-investing-advice-strategies-from-bullish-george-milling-stanley-2020-8">A 50-year gold vet and co-creator of its largest ETF shared 2 strategies investors should be using now amid the rise to new highs — and told us why his 'bull-case scenario' hasn't yet come to pass</a>The deal calls for Novavax to begin supplying the 60 million doses as early as the first quarter of 2021.Shares of biotech firms including Novavax, <a href="https://markets.businessinsider.com/stocks/mrna-stock">Moderna</a>, <a href="https://markets.businessinsider.com/stocks/pfe-stock">Pfizer</a>, and <a href="https://markets.businessinsider.com/stocks/gild-stock">Gilead</a> have all enjoyed sharp rallies throughout the year on positive vaccine news. Nearly 140 vaccines are currently in preclinical evaluation around the world and 29 are undergoing clinical trials, according to the <a href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines">World Health Organization</a>.Novavax <a href="https://markets.businessinsider.com/news/stocks/novavax-stock-price-after-promising-coronavirus-vaccine-trial-results-covid19-2020-8-1029472549">leaped as much as 21%</a> on August 5 after revealing its vaccine was generally well-tolerated and elicited robust antibody responses in patients during an early trial.The stock posted similarly healthy gains in July after the Trump administration revealed a $1.6 billion deal with Novavax to develop and manufacture its vaccine. The deal, made through the Operation Warp Speed initiative, plans to deliver 100 million doses of Novavax's vaccine by the end of 2020.Novavax traded at $144.31 per share as of 12:20 p.m. ET, up 3,510% year-to-date.Now read more <keyword id="31671" type="CITY" weightage="100" keywordseo="markets">markets</keyword> coverage from Markets Insider and Business Insider:<a href="https://markets.businessinsider.com/currencies/news/federal-reserve-digital-currency-coin-research-mit-possible-lael-brainard-2020-8-1029505035">Fed governor says central bank will partner with MIT on possible digital currency</a><a href="https://markets.businessinsider.com/news/stocks/tesla-stock-upgraded-price-target-boosted-morgan-stanley-battery-day-2020-8-1029505357">Morgan Stanley upgrades Tesla stock and boosts price target on high hopes for battery business</a><a href="https://www.businessinsider.com/stock-picks-long-short-investing-strategy-from-bank-of-america-2020-8">Bank of America shares a simple stock-trading strategy with a track record of repeatedly beating the market — including the 20 companies that best exploit it now</a><a href="https://markets.businessinsider.com/stocks/nvax-stock"><div type="image" title="NVAX" height="1362" width="1994" msid="77551521" hostid="261"></div></a>

Novavax soars 13% after inking deal with UK for 60 million doses of coronavirus vaccine

<ul class="summary-list"><li><keyword id="323030" type="COMPANY" weightage="60" keywordseo="Novavax">Novavax</keyword> shares have lost as much as 31% since Monday after news about its potential COVID-19 vaccine. </li><li>Novavax will now seek regulatory approval for its vaccine in the US, the <keyword id="6354868" type="COUNTRY" weightage="60" keywordseo="UK">UK</keyword> and in Europe in the third quarter. </li><li>The biotech company had previously projected potential US authorization in May. </li></ul><a href="https://markets.businessinsider.com/stocks/nvax-stock">Novavax shares</a> on Tuesday sharply extended losses during a two-day rout after the biotech company delayed seeking approval for its COVID-19 vaccine from three regulators, including the Food and Drug Administration.The shares came under pressure on Monday following a <a href="https://www.washingtonpost.com/health/2021/05/10/novavax-coronavirus-vaccine/">Washington Post report</a> that the company would delay filing for <keyword id="8974999" type="UNKNOWN" weightage="60" keywordseo="Emergency-Use-Authorization">emergency use authorization</keyword> for its experimental coronavirus vaccine in the US until June at the earliest, because of manufacturing issues. During a Monday conference call, Novavax reportedly said it expects to submit its vaccine to regulators in the US, the UK and the <keyword id="6355110" type="DEFINITION" weightage="60" keywordseo="european-union">European Union</keyword> in the third quarter.In March, Novavax CEO Stanley Erck said its coronavirus vaccine <a href="https://www.businessinsider.com/novavax-covid-vaccine-authorization-fda-approval-may-coronavirus-shot-erck-2021-3">could be authorized in the US as soon as May</a>. Shares of Novavax on Tuesday fell as much as 24% to $121.74. The shares on Monday plunged 8.8% following the Washington Post's report about the potential delay.Jefferies in a note Tuesday following Novavax's conference call said there not data as of yet has come from the company's phase 3 coronavirus study in the US, with Novavax anticipating top-line data before the end of the second quarter after modifying trial analysis protocol."Management remains confident in their ability to execute, and reiterated high demand for vaccine [worldwide] and the mid- to long-term opportunity that they have," said Jefferies equity analyst Kelechi Chikere in the note.However, pushing out the authorization filings to the third quarter from the second, and a downward revision to time to full production to the fourth quarter from the third, represent delays to prior timelines "and difficulty in growing," Chikere wrote. Jefferies has a buy rating on Novavax and a price target of $310 per share. Meanwhile, CFRA downgraded its rating on Novavax to "buy" from "strong buy" and cut its 12-month price target by $50 to $200. "We know that we are delayed from where we thought we would be at this point," Novavax CEO Stanley Erck said during Monday's conference call, according to the Washington Post. "Now, we're giving guidance that nearly all of the major challenges have been overcome and we can clearly see the light at the end of the tunnel."

Novavax extends 2-day loss to 31% as the biotech firm delays seeking emergency authorization for its COVID-19 vaccine

<ul><li><a href="https://markets.businessinsider.com/stocks/nvax-stock">Novavax</a> shares spiked as much as 41% on Tuesday after <a href="https://ir.novavax.com/news-releases/news-release-details/novavax-announces-16-billion-funding-operation-warp-speed">it said it would receive $1.6 billion from the US government</a> to develop its <keyword id="8624004" type="UNKNOWN" weightage="60" keywordseo="coronavirus-vaccine">coronavirus vaccine</keyword>.</li><li>The award is the largest yet from <keyword id="9233448" type="UNKNOWN" weightage="60" keywordseo="operation-warp-speed">Operation Warp Speed</keyword>, the Trump administration's plan to rapidly develop and deliver a <keyword id="1754604" type="PERSON" weightage="60" keywordseo="coronavirus">coronavirus</keyword> vaccine.</li><li><keyword id="323030" type="COMPANY" weightage="60" keywordseo="Novavax">Novavax</keyword> said part of the grant would fund a phase-three trial starting in the fall. It also said it planned to use the award to deliver 100 million vaccine doses by the end of the year.</li><li><a href="https://markets.businessinsider.com/stocks/nvax-stock">Watch Novavax trade live here</a>.</li></ul><a href="https://markets.businessinsider.com/stocks/nvax-stock">Novavax</a> stock surged as much as 41% on Tuesday after <a href="https://ir.novavax.com/news-releases/news-release-details/novavax-announces-16-billion-funding-operation-warp-speed">it said the US government would award it $1.6 billion</a> to fund its coronavirus vaccine trials and manufacturing.The grant is the largest yet from Operation Warp Speed, the Trump administration's plan to rapidly develop and deliver a coronavirus vaccine. Novavax said it aimed to use the funding for a phase-three trial beginning in the fall and for helping it to deliver 100 million doses by the end of the year."We are grateful to the U.S. government for its confidence in our technology platform, and are working tirelessly to develop and produce a vaccine for this global health crisis," President and CEO Stanley Erck said in a press release.Read more: <a href="https://www.businessinsider.com/tech-stocks-to-buy-ecommerce-picks-top-analyst-colin-sebastian-2020-7" target="_blank" rel="noopener">The most accurate analyst covering companies like Amazon says these 7 stocks are great bets for the future of e-commerce — even as the coronavirus bump fades</a>Novavax is among several biotech and pharmaceutical firms racing to introduce an effective treatment or vaccine for COVID-19. <a href="https://markets.businessinsider.com/stocks/mrna-stock">Moderna</a>, <a href="https://markets.businessinsider.com/stocks/gild-stock">Gilead</a>, <a href="https://markets.businessinsider.com/stocks/jnj-stock">Johnson &amp; Johnson</a>, <a href="https://markets.businessinsider.com/stocks/pfe-stock">Pfizer</a>, and <a href="https://markets.businessinsider.com/stocks/mrk-stock">Merck</a> are just some of the other companies testing their own compounds.<keyword id="31671" type="CITY" weightage="100" keywordseo="markets">Markets</keyword> are paying close attention too. Positive news from trials of leading candidates has typically lifted the stock market, while negative headlines have driven mass selling.The Operation Warp Speed award isn't Novavax's first from the US government. The Department of Defense granted $60 million to the biotech firm in June to help it produce 10 million doses of its vaccine candidate in 2020.Read more: <a href="https://www.businessinsider.com/stock-picks-to-buy-big-gains-q2-earnings-season-goldman-2020-7" target="_blank" rel="noopener">GOLDMAN SACHS: Buy these 13 stocks that are poised to crush the market within the next 2 weeks as earnings season gets underway</a>Though Novavax is now the biggest beneficiary of the administration's coronavirus vaccine effort, it's a late entry to the race. The company began human trials in May, well after rival firms had started testing. Novavax said that preliminary trial results were expected by the end of July and that phase-two trials would begin soon after.Novavax closed at $79.44 per share on Monday, up 1,887% year-to-date.Now read more markets coverage from Markets Insider and Business Insider:<a href="https://markets.businessinsider.com/news/stocks/economic-outlook-goldman-cuts-us-gdp-estimate-growth-expectations-q3-2020-7-1029369080">Goldman Sachs cuts US GDP estimate, now sees economy shrinking 4.6% in 2020</a><a href="https://markets.businessinsider.com/news/stocks/stock-market-outlook-prices-collapse-second-coronavirus-recession-gary-shilling-2020-7-1029370114">Stocks could fall 40% in a collapse mimicking the Great Depression, famed economist Gary Shilling says</a><a href="https://www.businessinsider.com/next-stock-market-crash-technical-analysis-indicators-to-watch-bofa-2020-7">Bank of America identifies 3 indicators that could make or break the stock market this summer – and warns they're all deteriorating fast</a><a href="https://markets.businessinsider.com/stocks/nvax-stock"><div type="image" title="NVAX" height="1486" width="1998" msid="76837049" hostid="261"></div></a>

Novavax skyrockets 41% after US government grants $1.6 billion for coronavirus vaccine creation

<ul><li>The AI Powered Equity ETF has doubled the performance of the S&amp;P 500 so far in 2023.</li><li>The strong outperformance comes as investors grow more interested in artificial intelligence after the release of ChatGPT.</li><li>These are the top 10 holdings in the AI Powered Equity ETF that's driven by IBM's Watson.</li></ul>Artificial intelligence <a href="https://markets.businessinsider.com/news/stocks/c3ai-stock-price-rally-openai-chatgpt-hype-artificial-intelligence-stocks-2023-2?_gl=1*1j9j2pc*_ga*MTkxNzQzNjc2Mi4xNjYxNDU2MDU1*_ga_E21CV80ZCZ*MTY3NTc4MjM1OS42OTYuMS4xNjc1NzgyNTAxLjAuMC4w">has been all the rage among investors this year</a> after the successful release of ChatGPT late last year sparked a craze among consumers and companies. One ETF has been utilizing aspects of artificial intelligence to drive its investment decisions since its launch in 2017: the <a href="https://markets.businessinsider.com/etfs/ai-powered-equity-etf-us26924g8134?miRedirects=1">AI Powered Equity ETF.</a>With $120 million in assets under management, the ETF has had a great start to 2023, posting year-to-date performance of about 14%. That's <a href="https://markets.businessinsider.com/news/etf/chatgpt-openai-ai-powered-equity-etf-aieq-ibm-watson-supercomputer-2023-1">about double the S&amp;P 500's year-to-date return of 7%.</a>The AIEQ ETF is actively managed and powered by IBM's Watson supercomputer. The fund utilizes machine learning, sentiment analysis, and natural language processing to pick the stocks in its portfolio. The portfolio analyzes companies via four quadrants, which include financial analysis, news, management, and macro.According to DataTrek Research, the ETF is currently fully invested, as it holds just 0.2% in cash and 151 individual stock positions. "These moves seem to reflect the algorithm's conviction in the continuation of a broad-based US equity market rally," DataTrek co-founder Jessica Rabe said in a Tuesday note. "Given current valuations, the US equity market is not expecting an economic contraction and nor is AIEQ, just based on its current stock picks."These are the top 10 holdings in the AI Powered Equity ETF that's driven by IBM's Watson supercomputer.10. APA Corporation<div type="image" title="Three oil and gas industry derricks" height="999" width="1999" msid="97703737" hostid="261" sizebytes="50702"></div>Ticker: <a href="https://markets.businessinsider.com/stocks/apa-stock">APA</a> % of ETF: 1.6% Industry: Oil &amp; Gas9. Prudential Financial<div type="image" title="Prudential Financial" height="1500" width="3000" msid="97703738" hostid="261" sizebytes="230444"></div>Ticker: <a href="https://markets.businessinsider.com/stocks/pru-stock">PRU</a> % of ETF: 1.7% Industry: Financial Services8. Roku<div type="image" title="Roku 2023 TV hanging on a wall with the Roku menu on screen." height="1000" width="2000" msid="97703739" hostid="261" sizebytes="197930"></div>Ticker: <a href="https://markets.businessinsider.com/stocks/roku-stock">ROKU</a> % of ETF: 1.9% Industry: Streaming Platform 7. Norwegian Cruise Line Holdings<div type="image" title="Norwegian Cruise Line's Norwegian Prima sailing by New York City" height="1249" width="2500" msid="97703740" hostid="261" sizebytes="431024"></div>Ticker: <a href="https://markets.businessinsider.com/stocks/nclh-stock">NCLH</a> % of ETF: 1.9% Industry: Cruise Ships 6. Celsius Holdings<div type="image" title="Cans of Celsius Heat energy drinks are seen in flavors including blueberry pomegranate, inferno punch, cherry lime, and jackfruit." height="491" width="983" msid="97703741" hostid="261" sizebytes="45748"></div>Ticker: <a href="https://markets.businessinsider.com/stocks/celh-stock">CELH</a> % of ETF: 1.9% Industry: Energy Drinks 5. Tesla<div type="image" title="A Tesla car dealership in Maplewood, Minnesota." height="3384" width="6768" msid="97703742" hostid="261" sizebytes="982046"></div>Ticker: <a href="https://markets.businessinsider.com/stocks/tsla-stock">TSLA</a> % of ETF: 2.8% Industry: Electric Vehicles 4. Zoetis<div type="image" title="Zoetis CEO Juan Ramon Alaix gives an interview following his company's IPO on the floor of the New York Stock Exchange, February 1, 2013. REUTERS/Brendan McDermid" height="400" width="800" msid="97703743" hostid="261" sizebytes="25008"></div>Ticker: <a href="https://markets.businessinsider.com/stocks/zts-stock">ZTS</a> % of ETF: 3.3% Industry: Animal Health 3. Constellation Energy<div type="image" title="wind power windmills" height="1200" width="2400" msid="97703744" hostid="261" sizebytes="104374"></div>Ticker: <a href="https://markets.businessinsider.com/stocks/ceg-stock">CEG</a> % of ETF: 3.5% Industry: Clean Energy 2. UnitedHealth Group<div type="image" title="A UnitedHealth Group health insurance card is seen in a wallet in this picture illustration October 14, 2019. REUTERS/Lucy Nicholson/Illustration" height="2016" width="4032" msid="97703745" hostid="261" sizebytes="362638"></div>Ticker: <a href="https://markets.businessinsider.com/stocks/unh-stock">UNH</a> % of ETF: 3.6% Industry: Health Insurance 1. Novavax<div type="image" title="Novavax Coronavirus Vaccine" height="1250" width="2500" msid="97703746" hostid="261" sizebytes="141642"></div>Ticker: <a href="https://markets.businessinsider.com/stocks/nvax-stock">NVAX</a> % of ETF: 4.3% Industry: Biotechnology

You Searched For "nvax" and got 8 results

Moderna and Novavax pare losses after Supreme Court strikes down Biden's vaccine mandate for private employers

Carla Mozée

Novavax surges 23% after scoring COVID-vaccine supply deal with the EU

Carla Mozée

Novavax climbs 11% after announcing data from UK vaccine trial are expected in early 2021

Ben Winck

Novavax climbs 9% after clinical trial shows the firm's COVID-19 vaccine is 90% effective

Carla Mozée

Novavax soars 13% after inking deal with UK for 60 million doses of coronavirus vaccine

Ben Winck

Novavax extends 2-day loss to 31% as the biotech firm delays seeking emergency authorization for its COVID-19 vaccine

Carla Mozée

Novavax skyrockets 41% after US government grants $1.6 billion for coronavirus vaccine creation

Ben Winck

These are the top 10 holdings of the AI-driven investment fund powered by Watson that has been crushing the market this year

Matthew Fox

Popular Keywords

Buying Guides